Company news

ImmuneOnco announces successful development of FcR-TANK cell line that will be used in combination with antibody for treatment of patients with cancer

2015-12-31 0:00:00Click:783

      ImmuneOnco Biopharmaceuticals Co., Ltd, an early-stage immunotherapy company dedicated to development and commercialization of novel cancer immunotherapy products, today announced a successful development of the first “X-TANK” product, FcR-TANK cell line that expresses FcγRIIIa with the polymorphism of valine at the 158 position. “We are proudly to announce that we have achieved a tremendous progress in developing our “X-TANK” products. We believe that with this newly developed FcR-TANK product, we will be able to provide an alternative approach to the treatment for patients with cancer”, said Dr. Wenzhi Tian, Founder and Chairman of ImmuneOnco.